Literature DB >> 7557528

Biobehavioral rehabilitation for older adults with essential tremor.

D A Lundervold1, R Poppen.   

Abstract

Essential tremor (ET), the most prevalent movement disorder, has a peak prevalence in the sixth decade of life. ET primarily affects the hands and head. Persons with ET are often significantly disabled in communication, work, leisure, domestic activities, and psychosocial adjustment. Medical intervention for ET is often limited in effectiveness. A biobehavioral rehabilitation model for older adults with ET is described.

Entities:  

Mesh:

Year:  1995        PMID: 7557528     DOI: 10.1093/geront/35.4.556

Source DB:  PubMed          Journal:  Gerontologist        ISSN: 0016-9013


  5 in total

1.  Estimating annual rate of decline: prospective, longitudinal data on arm tremor severity in two groups of essential tremor cases.

Authors:  Elan D Louis; Angus Agnew; Arthur Gillman; Marina Gerbin; Amanda S Viner
Journal:  J Neurol Neurosurg Psychiatry       Date:  2011-03-24       Impact factor: 10.154

Review 2.  Benefits and risks of pharmacological treatments for essential tremor.

Authors:  Kelly E Lyons; Rajesh Pahwa; Cynthia L Comella; Mahmood S Eisa; Rodger J Elble; Stanley Fahn; Joseph Jankovic; Jorge L Juncos; William C Koller; William G Ondo; Kapil D Sethi; Matthew B Stern; Caroline M Tanner; Ron Tintner; Ray L Watts
Journal:  Drug Saf       Date:  2003       Impact factor: 5.606

3.  Essential tremor as a neuropsychiatric disorder.

Authors:  Elan D Louis
Journal:  J Neurol Sci       Date:  2009-08-31       Impact factor: 3.181

4.  How many people in the USA have essential tremor? Deriving a population estimate based on epidemiological data.

Authors:  Elan D Louis; Ruth Ottman
Journal:  Tremor Other Hyperkinet Mov (N Y)       Date:  2014-08-14

5.  Worse and Worse and Worse: Essential Tremor Patients' Longitudinal Perspectives on Their Condition.

Authors:  Jesús Gutierrez; Jemin Park; Olufunmilayo Badejo; Elan D Louis
Journal:  Front Neurol       Date:  2016-10-13       Impact factor: 4.003

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.